XBB.1.5 makes up more than 40% of cases, the CDC says. While it’s more contagious, experts say it seems not to be more dangerous than earlier ones.
Author: Karen Weintraub, USA TODAY
As COVID turns 3, experts worry where the next pandemic will come from – and if we’ll be ready
Public health and national defense experts worry the next pandemic will come at an even higher price than this one. And the nation needs to be ready.
COVID-19 is about to explode in China. What that could mean for the United States.
Experts are predicting COVID cases in China will explode after the country ended its strict zero-COVID policy. Here’s how the US may be affected.
Parkinson’s disease is more common than thought. Toxins may contribute to rising rates.
Pinpointing the incidence rate of Parkinson’s disease can help bring more funding and research, experts say.
America has a pain problem. How can we find relief?
To better understand America’s pain problem and what to do about it, USA TODAY spoke with more than 50 pain experts and people with chronic pain.
NFL players age faster than the rest of us. Harvard is researching what can be done.
A Harvard study finds NFL players age a decade faster than the general population and are suffering young from arthritis and high blood pressure.
Weight loss treatment is on the verge of transformation. It’s not there yet. Here’s why.
New medicines like Wegovy promise dramatic weight loss, but there’s a long way to go to make anti-obesity drugs accessible to those who need them.
Where did mpox go? Here’s what brought down cases of disease formerly known as monkeypox.
Cases of the disease formerly known as monkeypox are down as the Biden administration declares an end to the public health emergency.
Stool tests like Cologuard are gaining popularity over colonoscopy. Which should you get?
Colonoscopy is recommended for people over 45, but preparation turns off many. Here’s a look at how it compares to stool tests FIT and Cologuard.
Experimental flu shot aims to target 20 influenza viruses in a single vaccine
Researchers want to target all 20 different types of influenza virus in a single shot. They have a new approach, using mRNA technology.